A new trading day began on Tuesday, with Cytokinetics Inc (NASDAQ: CYTK) stock price down -3.17% from the previous day of trading, before settling in for the closing price of $46.71. CYTK’s price has ranged from $44.49 to $86.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.05%. Meanwhile, its annual earnings per share averaged 4.19%. With a float of $113.56 million, this company’s outstanding shares have now reached $117.89 million.
Let’s determine the extent of company efficiency that accounts for 423 employees. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.77%, while institutional ownership is 113.10%. The most recent insider transaction that took place on Jan 07 ’25, was worth 98,640. In this transaction EVP Research & Development of this company sold 2,000 shares at a rate of $49.32, taking the stock ownership to the 116,071 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Officer proposed sale 12,000 for $49.19, making the entire transaction worth $590,280.
Cytokinetics Inc (CYTK) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.19% per share during the next fiscal year.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Here are Cytokinetics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1657.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach -5.31 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Looking closely at Cytokinetics Inc (NASDAQ: CYTK), its last 5-days average volume was 1.32 million, which is a jump from its year-to-date volume of 1.16 million. As of the previous 9 days, the stock’s Stochastic %D was 27.14%. Additionally, its Average True Range was 1.82.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 4.97%, which indicates a significant decrease from 13.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.52% in the past 14 days, which was lower than the 36.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $50.41, while its 200-day Moving Average is $55.73. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $46.76. Second resistance stands at $48.29. The third major resistance level sits at $49.27. If the price goes on to break the first support level at $44.24, it is likely to go to the next support level at $43.26. Should the price break the second support level, the third support level stands at $41.73.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
With a market capitalization of 5.34 billion, the company has a total of 118,014K Shares Outstanding. Currently, annual sales are 7,530 K while annual income is -526,240 K. The company’s previous quarter sales were 460 K while its latest quarter income was -160,550 K.
